Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04583527
Other study ID # CIP-0001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 11, 2020
Est. completion date August 16, 2021

Study information

Verified date July 2022
Source Alleviant Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with heart failure and preserved left ventricular ejection fraction (HFpEF, EF ≥ 50%) or mid-range left ventricular ejection fraction (HFmrEF, 40% < EF < 50%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using clinical, echocardiographic, and invasive hemodynamic data.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date August 16, 2021
Est. primary completion date August 16, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Documented history of NYHA Class II, Class III or ambulatory Class IV at the screening visit. 2. History of at least one hospitalization for treatment of heart failure within the past 12 months. 3. LVEF greater than 40% as measured by the study-specific transthoracic echocardiography. 4. Echocardiographic evidence of diastolic dysfunction documented by one or more of the following as measured by the study-specific transthoracic echocardiography protocol performed during screening: - LA diameter greater than 4 cm - LA volume index greater than 28 mL - Lateral e' less than 10 cm/s - Septal e' less than 8 cm/s - Lateral E/e' greater than 10 - Septal E/e' greater than 15 5. Elevated left atrial pressure WITH a gradient compared to right atrial pressure (RAP) documented by: (1) end-expiratory PCWP at peak supine cycle ergometer exercise greater than or equa. to 25 mmHg AND (2) PCWP greater than RAP by greater than or equal to 5 mmHg, OR greater than or equal to 10 mmHg increase of end-expiratory PCWP at peak supine cycle ergometer exercise compared to resting PCWP AND PCWP greater than RAP by greater than or equal to 5 mmHg. Exclusion Criteria: 1. Presence of advanced heart failure defined as one or more of the following: - ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF. - Cardiac index less than 2.0 L/min/m2. - Patient is on the cardiac transplant waiting list. - Inotropic infusion (continuous or intermittent) for EF less than 40% within the past 6 months. 2. Presence of moderate or worse valve disease, defined as one or more of the following: - Moderate or worse mitral valve regurgitation or moderate or worse mitral stenosis. - Moderate or worse tricuspid valve regurgitation. - Moderate or worse aortic valve disease defined as moderate or worse AS or AI. 3. . Presence of chronic pulmonary disease defined by one or more of the following: - Requirement for continuous home oxygen use. - Hospitalization within the past 12 months for treatment of pulmonary disease. - Significant chronic pulmonary disease defined as FEV1 less than 50%. 4. Documented as currently requiring dialysis or estimated GFR less than 25ml/min/1.73m2 5. 6-minute walk distance less than 50 m or greater than 450 m performed during screening. 6. Documented atrial fibrillation with ventricular rate greater than 100 BPM at screening. 7. Presence of moderate or worse right heart dysfunction OR RV dysfunction defined as TAPSE less than 14 mm or RVFAC less than or equal to 30% 8. Presence of pulmonary hypertension with PASP greater than or equal to 70 mmHg OR PVR greater than 4 Wood units. 9. Presence of anatomic anomaly that precludes creation of interatrial shunt (including patent foramen ovale, atrial septal defect, target septal thickness greater than 3 mm) 10. SBP greater than 170 mmHg at screening. 11. Documented left ventricular end diastolic diameter greater than 6 cm.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ALV1 System
The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.

Locations

Country Name City State
Georgia Tbilisi Heart & Vascular Tbilisi

Sponsors (1)

Lead Sponsor Collaborator
Alleviant Medical, Inc.

Country where clinical trial is conducted

Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The composite incidence of one or more of the following through the 1-month follow-up visit: major adverse cardiac, cerebrovascular and thromboembolic events. At one month
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy